| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10965666 | Vaccine | 2014 | 7 Pages |
Abstract
The AT20 peptide-based approach has allowed to redirect HAART-treated patients' humoral responses toward a previously untargeted hotspot of functional activity. Overall, the tested AT20-KLH doses were safe and well tolerated, supporting further exploration of AT20-KLH as an HIV-1 therapeutic vaccine candidate.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Maria Luisa Iaria, Simona Fiorentini, Emanuele Focà , Sonia Zicari, Cinzia Giagulli, Francesca Caccuri, Daniela Francisci, Giovanni Di Perri, Francesco Castelli, Franco Baldelli, Arnaldo Caruso,